Business, energy, technology, markets and global industry news from Business News Today

long-acting reversible contraception

Medical Devices & Diagnostics

Organon reports 3.9% six-year pregnancy rate with hormone-free MIUDELLA IUD

Organon has reported a cumulative six-year Pearl Index of 0.93 and an estimated pregnancy rate of 3.9% for the hormone-free MIUDELLA intrauterine system. The findings support an FDA application to extend its approved use from three to six years, with a decision expected in the second quarter of 2027.

Read More
Medical Devices & Diagnostics

Organon & Co. strengthens LARC strategy with MIUDELLA license from Sebela Pharmaceuticals

Organon & Co. licenses MIUDELLA copper IUD. Explore what this means for hormone-free contraception and LARC competition. Read the analysis.

Read More
Pharma & Biotech

Organon’s NEXPLANON earns five-year approval: How this changes the LARC landscape

FDA approves NEXPLANON for five years of use with REMS program. Find out how this reshapes contraceptive access, safety, and policy impact.

Read More